Krystal Biotech (NASDAQ:KRYS) Sees Strong Trading Volume on Earnings Beat

Key Points

• Krystal Biotech reported a strong earnings beat with an EPS of $1.29, surpassing the consensus estimate of $1.20, which contributed to heightened investor interest and increased trading volume.
• Despite a slight decline in stock price, multiple analysts maintain a buy rating for KRYS, with a consensus target price of $211.33 reflecting optimism about the company's future prospects.
• Insider trading activity shows significant sales, including a sale of 1,389 shares by insider Suma Krishnan, indicating ongoing trading by company executives but also retaining a substantial ownership stake.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) saw strong trading volume on Monday following a better than expected earnings announcement. 279,432 shares traded hands during mid-day trading, a decline of 13% from the previous session's volume of 319,447 shares.The stock last traded at $136.42 and had previously closed at $156.98.

The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.

Analyst Ratings Changes

KRYS has been the subject of several research analyst reports. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. Finally, Bank of America dropped their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of "Buy" and a consensus target price of $210.22.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently made changes to their positions in KRYS. Brooklyn Investment Group boosted its holdings in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after purchasing an additional 179 shares during the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech during the first quarter worth $29,000. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock worth $34,000 after purchasing an additional 166 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Up 1.9%

The firm has a fifty day moving average price of $141.94 and a 200-day moving average price of $155.36. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of 28.18 and a beta of 0.70.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).